6-methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide | 442548-70-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide
• 英文别名: 6-methoxy-8-(4-methylpiperazin-1-yl)-4-oxo-N-(4-piperazin-1-ylphenyl)chromene-2-carboxamide
• CAS: 442548-70-1
• 化学式: C₂₆H₃₁N₅O₄
• 分子量: 477.563
• InChiKey: OTCAWDMXJIBVTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  86.4
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  1-吡咯烷羰酰氯 、 6-methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide 生成 6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid {4-[4-(1-pyrrolidin-1-yl-methanoyl)-piperazin-1-yl]-phenyl}-amide
  参考文献：
  名称：

  Therapeutic Heterocyclic Compounds 507

  摘要：

  本文提供的化合物具有以下公式（I）：其中这些化合物可用于治疗精神障碍，包括但不限于抑郁症、广泛性焦虑症、进食障碍、痴呆症、恐慌症和睡眠障碍。这些化合物也可能有助于治疗胃肠障碍、心血管调节、运动障碍、内分泌障碍、血管痉挛和性功能障碍。这些化合物是5HT1B和5HT1D受体拮抗剂。

  公开号：

  US20080076759A1
• 作为产物：
  描述：

  4-[4-({1-[6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-methanoyl }-amino)-phenyl]-piperazine-1-carboxylic acid Tert-butyl Ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 6-methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide
  参考文献：
  名称：

  Therapeutic chroman compounds

  摘要：

  本文提供的是一种化合物，其化学式表示为（I），其中这些化合物对治疗偏头痛有用。还提供了制备化合物（I）和中间体的方法。

  公开号：

  US20040110745A1

文献信息

• Therapeutic heterocyclic compounds
  申请人：——

  公开号：US20030013708A1

  公开（公告）日：2003-01-16

  Provided herein is a compound having the formula (I): 1 Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT 1B and 5HT 1D antagonists.

  本文提供的化合物具有以下式（I）： 其中所述化合物可用于治疗精神障碍，包括但不限于抑郁症、广泛性焦虑、进食障碍、痴呆症、恐慌障碍和睡眠障碍。这些化合物还可能用于治疗胃肠道障碍、心血管调节、运动障碍、内分泌障碍、血管痉挛和性功能障碍。这些化合物是5HT 1B和5HT 1D拮抗剂。
• Therapeutic chromone compounds
  申请人：——

  公开号：US20040087575A1

  公开（公告）日：2004-05-06

  Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT 1B antagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.

  本文提供的是一种化合物，其化学式为（I），其中该化合物可用于治疗包括但不限于抑郁症、广泛性焦虑、进食障碍、痴呆症、恐慌障碍和睡眠障碍在内的精神疾病。这些化合物也可能对治疗胃肠道疾病、心血管调节、运动障碍、内分泌失调、血管痉挛和性功能障碍有用。这些化合物是5HT 1B 拮抗剂。本文还提供了制备化合物（I）和中间体化合物的方法。
• Therapeutic quinolone compounds with 5-ht-antagonistic properties
  申请人：Haeberlein Markus

  公开号：US20050085457A1

  公开（公告）日：2005-04-21

  Provided herein is a compound having the formula (I) (R 2 is typically a tertiary nitrogen atom, being either alkyl-substituted or member of q heterocyclic ring; R 7 is typically a monocyclic or bicyclic aromatic ring or a heterocyclic ring) wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT 1B and 5HT 1D antagonists.

  本文提供的化合物具有公式（I）（其中，R2通常是三级氮原子，可以是烷基取代或q杂环环成员; R7通常是单环或双环芳香环或杂环环），其中所述化合物可用于治疗精神障碍，包括但不限于抑郁症、广泛性焦虑、进食障碍、痴呆症、惊恐障碍和睡眠障碍。这些化合物还可以用于治疗胃肠道疾病、心血管调节、运动障碍、内分泌障碍、血管痉挛和性功能障碍。这些化合物是5HT1B和5HT1D拮抗剂。
• Therapeutic quinoline compounds
  申请人：Haeberlein Markus

  公开号：US20060178372A1

  公开（公告）日：2006-08-10

  Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT 1B and 5HT 1D antagonists.

  本文提供的化合物具有公式（I）：其中所述的化合物可用于治疗精神障碍，包括但不限于抑郁症，广泛性焦虑症，进食障碍，痴呆症，惊恐障碍和睡眠障碍。该化合物还可以用于治疗胃肠道疾病，心血管调节，运动障碍，内分泌障碍，血管痉挛和性功能障碍。该化合物是5HT1B和5HT1D拮抗剂。
• US7285662B2
  申请人：——

  公开号：US7285662B2

  公开（公告）日：2007-10-23